Intracellular modulators of apoptopic cell death pathways
AssigneeApplied Research Systems ARS Holding N.V.
InventorCarlo Riccardi
Life of this patent
Estimating the term…
Abstract
A DNA sequence encoding a glucocorticoid-induced leucine-zipper family related protein (GILR), isoforms, fragments or analogs thereof, said GILR, isoforms, fragments or analogs thereof capable of inhibiting apoptosis and stimulating lymphocyte activity, GILR proteins, isoforms, analogs, fragments and derivatives thereof encoded by the aforesaid DNA sequence, their preparation and uses.
Claims5
A transgenic mouse having integrated in its genome a nucleic acid construct, comprising a human CD2 promoter and a human CD2 locus control region operably linked to a mammalian Glucocorticoid Induced Leucine-Zipper (GILZ) cDNA sequence, wherein said transgenic mouse expresses GILZ in thymocytes at an elevated level compared to a non-transgenic mouse and wherein the elevated expression of GILZ results in a significant decrease in CD4+ CD8+ double positive cells and increase in CD4− CD8− double negative cells and CD8+ single positive cells when compared with a non-transgenic mouse.
A method of producing a transgenic mouse whose genome comprises a nucleic acid construct, wherein said construct comprises a human CD2 promoter and a human CD2 locus control region operably linked to a mammalian Glucocorticoid Induced leucine-Zipper (GILZ) cDNA sequence, said method comprising:
- transferring a nucleic acid construct comprising a human CD2 promoter and a human CD2 locus control region operably linked to a mammalian GILZ cDNA sequence to a fertilized mouse oocyte;
- allowing the zygote resulting from the fertilized mouse oocyte to develop to term, thereby obtaining a transgenic mouse whose genome comprises the nucleic acid construct;
- breeding said transgenic mouse with a non-transgenic mouse to generate offspring;
- and
- selecting from the offspring a transgenic mouse whose genome comprises the nucleic acid construct, wherein said transgenic mouse expresses GILZ in thymocytes at an elevated level compared to a non-transgenic mouse and wherein the expression of GILZ results in a significant decrease in CD4+ CD8+ double positive cells and increase in CD4− CD8− double negative cells and CD8+ single positive cells when compared with a non-transgenic mouse.
Dependencies are inferred from the claim text.